Use of the RBANS to Evaluate Cognition in Patients with Schizophrenia and Metabolic Syndrome: a Meta-Analysis of Case-Control Studies

Zheng, Wei; Jiang, Weihang; Zhang, Xun; Cai, Duan; Sun, Junjun; Yin, Fei; Ren, Pengcheng; Zhao, Min; Wu, Huawang; Xiang, Yong; Wan, Liang

doi:10.1007/s11126-021-09889-9

Cited by 14 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The raw total scores of the subscales were subsequently processed into standardized scores. The RBANS has demonstrated good reliability and validity in patients with schizophrenia and in the Chinese population [25].…”

Section: Clinical and Cognitive Assessmentmentioning

confidence: 98%

Association between elevated serum matrix metalloproteinase-2 and tumor necrosis factor-α, and clinical symptoms in male patients with treatment-resistant and chronic medicated schizophrenia

Yang,

Peng,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Inflammation has an important role in the pathogenesis of schizophrenia. The aim of this study was to investigate the levels of tumor necrosis factor (TNF) and matrix metalloproteinase-2 (MMP-2) in male patients with treatment-resistant schizophrenia (TRS) and chronic medicated schizophrenia (CMS), and the relationship with psychopathology. Methods: The study enrolled 31 TRS and 49 CMS male patients, and 53 healthy controls. Serum MMP-2 and TNF-a levels were measured by the Luminex liquid suspension chip detection method. Positive and Negative Syndrome Scale (PANSS) scores were used to evaluate symptom severity and Repeatable Battery for the Assessment of Neuropsychological Status was used to assess cognitive function. Results: Serum TNF-a and MMP-2 levels differed significantly between TRS, CMS and healthy control patients (F=4.289, P=0.016; F=4.682, P=0.011, respectively). Bonferroni correction demonstrated that serum TNF-a levels were significantly elevated in CMS patients (P=0.022) and MMP-2 levels were significantly higher in TRS patients (P=0.014) compared to healthy controls. In TRS patients, TNF-a was negatively correlated with age (r=-0.435, P=0.015) and age of onset (r=-0.409, P=0.022). In CMS patients, MMP-2 and TNF-a were negatively correlated with PANSS negative and total scores, and TNF-a was negatively correlated with PANSS general psychopathology scores (all P<0.05). MMP-2 levels were positively correlated with TNF-a levels (P<0.05), but not with cognitive function (P>0.05). Conclusion: The results indicate the involvement of inflammation in the etiology of TRS and CMS. Further studies are warranted.

show abstract

Section: Clinical and Cognitive Assessmentmentioning

confidence: 98%

Association between elevated serum matrix metalloproteinase-2 and tumor necrosis factor-α, and clinical symptoms in male patients with treatment-resistant and chronic medicated schizophrenia

Yang,

Peng,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Nonetheless, they are established for this purpose. 25,26 The WIE is a test battery to measure overall cognitive functioning. It comprises several subtests and allows to determine an index value for working memory.…”

Section: Neurocognitive Parameters and Interpretationmentioning

confidence: 99%

The relationship between blood–brain barrier dysfunction and neurocognitive impairments in first-episode psychosis: findings from a retrospective chart analysis

et al. 2023

View full text Add to dashboard Cite

Background Even before the onset of psychotic symptoms, individuals with schizophrenia display cognitive impairments. Simultaneously, increasing amounts of individuals exhibit dysfunction of the blood–brain barrier (BBB). However, the impact of BBB dysfunction on neurocognitive impairment in people with first-episode psychosis has not yet been investigated. Aims To advance understanding of said relationship, we considered one of the largest first-episode psychosis cohorts with cerebrospinal fluid parameters available, and investigated whether BBB dysfunction is related to working memory, working speed and attention. Method We conducted a retrospective chart review of 121 in-patients diagnosed with a first episode of a schizophrenia spectrum disorder. Patients underwent neurocognitive testing and a lumbar puncture within routine clinical care. To define BBB dysfunction, albumin cerebrospinal fluid/serum quotients, immunoglobulin G ratios and oligoclonal band types were evaluated, and gender-specific differences investigated. Neurocognitive functioning was assessed by the Wechsler Adult Intelligence Scale, Test of Attentional Performance and Repeatable Battery for the Assessment of Neuropsychological Status. We performed simple and multiple linear regression analyses to interpret associations of interest. Results Of those tested, 16% showed an alteration in albumin quotients and 12% had an oligoclonal band type indicating BBB dysfunction. Notably, male patients were more likely to have an increased albumin quotient and a higher immunoglobulin G ratio than female patients. We found no significant association between BBB dysfunction and neurocognitive assessments. Conclusions The hypothesised relationship between BBB and neurocognitive impairments was not detectable in our retrospective cohort. Further cerebrospinal fluid-based studies with a longitudinal assessment of cognitive functioning and disease trajectory are urgently needed.

show abstract

“…MET have strongly deleterious effects on brain integrity including accelerated brain aging, lower cognitive scores, formation of hyperintensive white matter necrotic regions and higher rates of dementia (Angoff et al, 2022 ; Du et al, 2022 ; Marseglia et al, 2021 ). Neuroimaging studies in psychiatric illnesses may not fully account for higher rates of MET in patients versus controls, and some of the brain effects reported in mental disorders may be due to higher rates of MET comorbidity in people with mental illnesses (Ferri et al, 2021 ; Ryan et al, 2022 ; Zheng et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

“…Neuroimaging studies in psychiatric illnesses may not fully account for higher rates of MET in patients versus controls, and some of the brain effects reported in mental disorders may be due to higher rates of MET comorbidity in people with mental illnesses (Ferri et al, 2021;Ryan et al, 2022;Zheng et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Brain deficit patterns of metabolic illnesses overlap with those for major depressive disorder: A new metric of brain metabolic disease

Hatch

Gao

et al. 2023

Human Brain Mapping

View full text Add to dashboard Cite

Metabolic illnesses (MET) are detrimental to brain integrity and are common comorbidities in patients with mental illnesses, including major depressive disorder (MDD). We quantified effects of MET on standard regional brain morphometric measures from 3D brain MRI as well as diffusion MRI in a large sample of UK BioBank participants. The pattern of regional effect sizes of MET in non‐psychiatric UKBB subjects was significantly correlated with the spatial profile of regional effects reported by the largest meta‐analyses in MDD but not in bipolar disorder, schizophrenia or Alzheimer's disease. We used a regional vulnerability index (RVI) for MET (RVI‐MET) to measure individual's brain similarity to the expected patterns in MET in the UK Biobank sample. Subjects with MET showed a higher effect size for RVI‐MET than for any of the individual brain measures. We replicated elevation of RVI‐MET in a sample of MDD participants with MET versus non‐MET. RVI‐MET scores were significantly correlated with the volume of white matter hyperintensities, a neurological consequence of MET and age, in both groups. Higher RVI‐MET in both samples was associated with obesity, tobacco smoking and frequent alcohol use but was unrelated to antidepressant use. In summary, MET effects on the brain were regionally specific and individual similarity to the pattern was more strongly associated with MET than any regional brain structural metric. Effects of MET overlapped with the reported brain differences in MDD, likely due to higher incidence of MET, smoking and alcohol use in subjects with MDD.

show abstract

Use of the RBANS to Evaluate Cognition in Patients with Schizophrenia and Metabolic Syndrome: a Meta-Analysis of Case-Control Studies

Cited by 14 publications

References 46 publications

Association between elevated serum matrix metalloproteinase-2 and tumor necrosis factor-α, and clinical symptoms in male patients with treatment-resistant and chronic medicated schizophrenia

Association between elevated serum matrix metalloproteinase-2 and tumor necrosis factor-α, and clinical symptoms in male patients with treatment-resistant and chronic medicated schizophrenia

The relationship between blood–brain barrier dysfunction and neurocognitive impairments in first-episode psychosis: findings from a retrospective chart analysis

Brain deficit patterns of metabolic illnesses overlap with those for major depressive disorder: A new metric of brain metabolic disease

Contact Info

Product

Resources

About